1
|
Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, Virgilis D, Neu-Yilik G, Kulozik AE, Kerem E, Kerem B. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007; 117:683-92. [PMID: 17290305 PMCID: PMC1783999 DOI: 10.1172/jci28523] [Citation(s) in RCA: 217] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2006] [Accepted: 12/12/2006] [Indexed: 11/17/2022] Open
Abstract
Aminoglycosides can readthrough premature termination codons (PTCs), permitting translation of full-length proteins. Previously we have found variable efficiency of readthrough in response to the aminoglycoside gentamicin among cystic fibrosis (CF) patients, all carrying the W1282X nonsense mutation. Here we demonstrate that there are patients in whom the level of CF transmembrane conductance regulator (CFTR) nonsense transcripts is markedly reduced, while in others it is significantly higher. Response to gentamicin was found only in patients with the higher level. We further investigated the possibility that the nonsense-mediated mRNA decay (NMD) might vary among cells and hence governs the level of nonsense transcripts available for readthrough. Our results demonstrate differences in NMD efficiency of CFTR transcripts carrying the W1282X mutation among different epithelial cell lines derived from the same tissue. Variability was also found for 5 physiologic NMD substrates, RPL3, SC35 1.6 kb, SC35 1.7 kb, ASNS, and CARS. Importantly, our results demonstrate the existence of cells in which NMD of all transcripts was efficient and others in which the NMD was less efficient. Downregulation of NMD in cells carrying the W1282X mutation increased the level of CFTR nonsense transcripts and enhanced the CFTR chloride channel activity in response to gentamicin. Together our results suggest that the efficiency of NMD might vary and hence have an important role in governing the response to treatments aiming to promote readthrough of PTCs in many genetic diseases.
Collapse
Affiliation(s)
- Liat Linde
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Stephanie Boelz
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Malka Nissim-Rafinia
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Yifat S. Oren
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Michael Wilschanski
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Yasmin Yaacov
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Dov Virgilis
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Gabriele Neu-Yilik
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Andreas E. Kulozik
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Eitan Kerem
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Batsheva Kerem
- Department of Genetics, Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel.
Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
Department for Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany.
CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel
| |
Collapse
|